Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma By Ogkologos - October 24, 2025 378 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENRICH study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Sleep Issue Called Hypersomnolence Can Increase The Risk Of Diabetes And... May 14, 2020 Long-Term Benefit of Nivolumab Plus Low-Dose Ipilimumab in Previously Treated Patients... June 30, 2022 The UK Government’s response to Javed Khan’s tobacco review: A small... April 11, 2023 9-Year-Old Has His Final Cancer Treatment After 3 Years – Breaks... January 27, 2020 Load more HOT NEWS Moving target – retrotransposable elements and cancer Doctors Worry Breast Cancer Cases Are Being Missed as Mammogram Rates... Dress up that Salad! Patients less likely to rate cancer care as ‘very good’ during...
